Search PubMed⌕ Search

Biomedical subjects

H Takagi

Publications and source records attributed to H Takagi.

At least 1,495 records · Page 83Linked to original sources

Blood loss and ICG clearance as best prognostic markers of post-hepatectomy liver failure.

BACKGROUND/AIMS: Hepatic failure after hepatic resection is a lethal complication. Various factors affecting the occurrence of hepatic failure were examined. METHODOLOGY: The subjects were 315 patients who underwent hepatic resection for hepatocellular carcinoma during the 11-year period between 1985 and 1995. Univariate analyses of 14 variables were performed among living and dead patients after hepatic resection. With the significant prognostic variables obtained in the multivariate analysis, the predicted probability of death (PPD) was calculated for each patient. RESULTS: There were 291 survivors and 24 patients with post-operative liver failure. Among the factors showing statistical or near significance in the univariate analysis, KICG and blood loss were disclosed to be factors independently correlating with survival. PPD was calculated for each patient according to the following equation: PPD = 1/Exp(1.6766 - 0.0004394 x blood loss + 16.69 x KICG) + 1. Assessing the goodness-of-fit model by Hosmer-Lemeshow test indicated the model seemed to fit quite well. CONCLUSIONS: Minimizing the blood loss during hepatic resection is important to avoid post-operative liver failure. Careful hemostatic procedure is necessary for patients with unexpected massive blood loss during hepatic resection so as to prevent post-operative bleeding.

Adult↗

The effect of intraportal administration of prostaglandin E1 on liver blood flow and liver function.

BACKGROUND/AIMS: Prostaglandin E1 (PGE1) exerts a hepatic cytoprotective action directly and indirectly through enhancing hepatic blood flow. Although PGE1 is usually administered systemically, more than 60% of PGE1 is inactivated during only a single passage through the lung. By administering PGE1 intraportally the intrahepatic level of this drug can be increased effectively and liver dysfunction might be prevented. In this study, the effect of intraportal administration of PGE1 to patients who underwent hepatectomy was estimated. METHODOLOGY: Twenty patients who underwent hepatectomy from January 1995 to December 1996 were divided into 2 groups, i.e., a PGE1 group (n=8) and a control group (n=12). Laboratory data and hepatic portal blood flow were examined before and after hepatectomy. In the PGE 1 group, PGE 1 was continuously infused at a dose of 120 microg/day for 5 days through a catheter inserted into the portal vein via the gastroepiploic vein. RESULTS: There was no difference in the post-operative change in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) between the 2 groups. Elevation of total bilirubin was more significantly suppressed in the PG group than in the control group. Total branched-chain amino acids and the tyrosine ratio reached their peak on the 5th post-operative day (POD) and were significantly higher in the PG group. Post-operative portal blood flow was significantly increased in the PG group. CONCLUSIONS: Our results indicated that continuous intraportal administration of small doses of PGE1 is effective for the protection of hepatic function after hepatectomy.

Adult↗

Experimental studies of new embolizing material for portal vein embolization.

BACKGROUND/AIMS: Preoperative portal vein embolization induces hypertrophy of the future remnant liver and atrophy of the liver to be resected. This procedure has been used recently to avoid hepatic failure in extensive hepatic resection, but an adequate embolizing material has not been developed. This experimental study investigated the embolization effect of a newly devised embolizing material in dogs. METHODOLOGY: The left branch of the portal vein was embolized with an emulsion of polidocanol and gelatin sponge. We studied the changes in liver weight and biochemical data up to 8 weeks after embolization. Pathological examination of the embolized portal vein and radiological study of the embolizing effect were performed. RESULTS: Complete obstruction of the portal vein was maintained until 8 weeks after embolization. Sufficient hypertrophy of the non-embolized liver and atrophy of the embolized liver were obtained during this examination. No serious complication was observed. CONCLUSIONS: The mixture of polidocanol and gelatin sponge seems to ensure perfect portal embolization without recanalization. This embolizing material is suitable for portal embolization.

Animals↗

Cumulative results of chemosensitivity tests for antitumor agents in Japan. Japan Research Society for Appropriate Cancer Chemotherapy.

The Japan Research Society for Appropriate Cancer Chemotherapy set out to summarize the present status of chemosensitivity testing for antitumor agents in Japan. Two different questionnaires were sent to 122 and 94 institutes, respectively, whilst responses were received from 87 (71.3%) and 41 (43%) institutes, respectively. The results showed that chemosensitivity tests were performed in 42 institutes where a total of 2 in vivo and 10 in vitro different assays were performed. Actual cases of chemosensitivity detected by the tests varied from 1 to 368 cases/year/institute with a median of 15 cases and mean +/- standard deviation of 48 +/- 65 cases. The total number of tested cases increased from 1,747 cases in 1993 to 1,934 cases in 1994 and to 2,147 cases in 1995, resulting in an average of 1,891 cases year. The assays used included the adenosine triphopsphate inhibition assay,/the collagen droplet embed drug response assay, the fluorescent dye assay, the growth chamber assay, the histoculture drug response assay, human tumor clonogenic assay, the MTT assay (SDI test), the nuclear damage assay, the nude mouse model, the subrenal capsule assay and the thymidine incorporation assay (scintillation assay). The correlation of in vitro and in vivo results revealed 215 true positive (S/S), 246 false positive (S/R), 45 false negative (R/S) and 595 true negative (R/R) cases, resulting in rates of 47% for true positives and 93% for true negatives, with a 74% accuracy. We concluded that chemosensitivity testing is widely applied in this country and has a high accurate predictive value for advanced carcinomas.

Animals↗

Optimum duration of oral adjuvant chemotherapy of HCFU for colorectal cancer; review of 5-year follow-up.

PURPOSE: To investigate the optimal duration of oral HCFU administration for minimization of side effects induced by long-term administration. PATIENTS AND METHODS: In total, 155 patients allocated to two groups of different duration of the therapy were reviewed: twice or three times per day doses of oral HCFU (8 mg/Kg body weight/day) for 3 months vs. 12 months. RESULTS: Though statistically significant difference was not found in cumulative survival and disease-free rates between the groups due to so many violations of duration of therapy, when reanalyzing the variables in order of real duration of therapy, those rates were significantly higher in patients treated for 300 and more days than less than 300 days (g-Wilcoxon test: p < 0.04). No significant difference was observed in the background factors between the groups. CONCLUSION: At least 300 days is suggested to be necessary to obtain the optimal effectiveness of adjuvant chemotherapy for curatively resected colorectal cancer.

Administration, Oral↗

An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancer.

To reappraise the benefits of the long supported chemotherapy with carmofur, a meta-analysis based on individual patient data from the three clinical trials was performed by pooling 614 patients from three trials, there is a statistically significant survival benefit (2p=0.032) and disease-free survival (DFS) benefit (2p=0.021) for carmofur; and a highly significant advantage for carmofur in DFS (2p=0.0004) and in survival (2p=0.004) in Dukes' C patients. This IPD meta-analysis strongly suggested an effect of oral carmofur in a long supported chemotherapy for curatively resected colorectal carcinoma.

Administration, Oral↗

Cyclosporin A is a hormonal immunomodulator. I. Human study.

The immunosuppressant Cyclosporin A (CS) is known to induce 2 hormonal disorders as side effects of its long-term use: gynecomastia in male subjects and hirsutism in female subjects. The present study was started to investigate the problem of whether or not the above steroid-mimetic actions of CS are to be related to the immunosuppressive effect of that substance. Practically, a case-control comparison of 14 urinary steroid excretions was made for each sex with healthy controls and kidney transplant recipients undergoing CS-free and CS-dependent immunosuppressive treatments on the one hand, and the success rate of kidney transplantation was compared between the CS-free treatment group and the CS-dependent treatment group on the other hand. The results obtained are follows: 1) Both the CS-free- and CS-dependent-treatments produced a general depression of all androgens, progestins and corticosteroids in the urine. The suppressive effect on urinary steroid excretions was more marked in the latter than in the former. Under the same CS-free treatment, the excretion of tetrahydrocortisol (THF) was intact in male patients and was significantly depressed in female patients. 2) A remarkable difference between the 2 immunosuppressive treatment groups was found in the ratio of urinary androsterone (AD) to urinary THF, an index of androgen to glucocorticoid balance: the praxis of CS-free treatment significantly depressed log AD/THF in patients of both sexes, the ratio being much higher in normal males than in normal females.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenal Cortex Hormones↗

A newly developed drug delivery system using fine particles of activated charcoal for targeting chemotherapy.

Targeting chemotherapy to the metastatic lesions of the lymph nodes after surgical removal of the main tumor, a drug delivery system using ultrafine particles of activated charcoal was developed and examined for its ability to adsorb mitomycin C (MMC) and to transport MMC to the lymph system. Satisfactory results were obtained. In animal experiments, serial sampling of thoracic duct lymph by cannulation and serial samplings of peripheral vein blood after injection of MMC-charcoal solution into the subserosal space of the intestinal wall were made to study the pharmacodynamics of the lymph-blood system through analysis of MMC regression curves. Clearance (K) and half-life (t1/2) are calculated from the formula; C(t) = C(t0) X e-kt, and compared with that of MMC-saline. Activated charcoal has a proven ability to transport MMC to the lymphatic system. With activated charcoal, MMC is retained for much longer in the lymph nodes than with saline. Congestion of the lymph system was produced by ligation of the thoracic duct in CH-40, with 25% prolongation of t1/2. In conclusion, these drug delivery systems are suitable for targeting chemotherapy at lymph node metastases, and it is proven that 1500 AA Mitsubishi ultrafine charcoal is a good carrier of drug and a slow drug-release material in the lymphatics. Minimal side effects are expected because of the constant low concentrations in the general circulation.

Animals↗

The surgical treatment of cancer of the stomach.

From 1965 to 1977, 2421 patients with gastric cancer underwent operation in our hospital. 66% were males (mean age 55.9 years) and 34% females (mean age 52.2 years); 31% had a mucosal (m) and submucosal cancer (sm); 16.8% had intramuscular cancer (pm); a curative operation was performed in 62.0% of cases. The five and ten year survival rates of the advanced cancer group are 52.5% and 42.3%, whereas in the early cancer cases they are 95.0% and 85.4% respectively. These five and ten-year survival rates are significantly lower in patients with lymph node metastasis (43.3% and 35.4%). Thirty five per cent of the patients who underwent resection from 1957 to 1963 required an enlarged total gastrectomy, compared with 15% in the present series.

Adult↗

Evidence that donor pretreatment with FK506 has a synergistic effect on graft prolongation in hamster-to-rat heart xenotransplantation.

BACKGROUND: Concordant xenografts are rejected in a different fashion than are discordant xenografts or allografts. We tested the effect of donor pretreatment with the use of FK506 combined with posttransplantation FK506 treatment and splenectomy and analyzed the mechanism of rejection in hamster-to-rat heart xenotransplantation. METHODS: Heart xenotransplantation from hamster to rat was carried out under immunosuppression with the use of donor pretreatment with FK506, posttransplantation FK506 treatment and splenectomy, followed by complement-dependent cytotoxicity assay, delayed type hypersensitivity test, and histologic analysis. RESULTS: The cardiac graft survived 3 days without donor pretreatment, whereas it survived 4.8 days with donor pretreatment with FK506 (5 mg/kg for 3 days). The graft survival was synergistically enhanced by donor pretreatment, posttransplantation FK506 therapy, and splenectomy, and the longest survival was 43.6 +/- 7.7 days in the group with donor pretreatment, posttransplantation FK506 therapy for 4 weeks, and splenectomy. Delayed-type hypersensitivity response was suppressed significantly in the donor pretreatment group. The antibody typed by immunoglobulin M was mainly detected in the rat serum with the rejected grafts by complement-dependent cytotoxicity assay. Correlating with this complement-dependent cytotoxicity titer, neutrophil infiltration and vasculitis of the coronary vessels were recognized in the rejected grafts, and the marginal zone of the white pulp expanded in the spleen. CONCLUSIONS: Donor pretreatment with FK506 combined with posttransplantation FK506 therapy and splenectomy suppresses the outlet antigen, immunoglobulin M production, and lymphocyte activation, thereby prolonging the graft survival in hamster-to-rat heart xenotransplantation.

Animals↗

Immunohistochemical detection of endotoxin in endotoxemic rats.

BACKGROUND/AIMS: Although there are various methods to detect endotoxin mainly after the intravenous injection of purified endotoxin in a host, its uptake and distribution among the various organs is not well understood. In the present study, the time course of the distribution and disappearance of endotoxin in various rat organs following injection via two different routes was evaluated by an immunohistochemical staining method using a newly developed monoclonal antibody against Factor C. MATERIALS AND METHODS: The time course of the distribution of lipopolysaccharide (LPS) into the liver, spleen, lung, and kidney after intravenous (i.v.) or intraperitoneal (i.p.) injection of LPS was studied by immunohistochemical staining using a newly developed monoclonal antibody against Factor C in rats. Moreover, plasma endotoxin levels were measured by a modification of a chromogenic endotoxin-specific assay. RESULTS: At 30 minutes after injection in the i.v. group and at 12 and 24 hours in the i.p. group, endotoxin was present on Kupffer cells by staining and on some sinusoidal endothelial cells in the liver as well as on macrophages in the marginal zone of the spleen. The plasma endotoxin levels in the i.v. group decreased gradually after injection. However, levels in the i.p. group gradually increased, reaching a maximum level at 6 hours after injection, and then gradually decreasing. CONCLUSION: These results suggest that, regardless of the route of injection, endotoxin can be detected by an immunohistochemical staining method using a monoclonal antibody against Factor C.

Animals↗

Intraportal endovascular ultrasonography as a new diagnostic procedure in pancreatic surgery.

BACKGROUND/AIMS: This presents the results of a prospective study on the use of intraportal endovascular ultrasonography (IPEUS) as a screening tool for pancreatic carcinoma. PATIENTS AND METHODS: Twenty-four patients with pancreatic cancer (17 head, 7 body) were studied for portal vein invasion using intraportal endovascular ultrasonography (IPEUS). In 22 cases, IPEUS was performed intraoperatively from the superior mesenteric venous route with an 8-French, 20 MHz intravascular ultrasound (IVUS) catheter, in two cases preoperatively from the percutaneous transhepatic route with a 6- French, 20 MHz IVUS catheter. The sonographic criterion for detection of portal venous invasion was obliteration of the echogenic band of the portal vein. The IPEUS results were compared with those of CT and portography. RESULTS: Vascular invasion was confirmed with resected specimens in nine cases and with operative findings in three patients. For diagnosis of portal venous invasion, the sensitivity, specificity, and overall accuracy of IPEUS were 100%, 91.7%, and 95.8% respectively. For portography, the equivalent values were 66.7%, 75%, and 70.8%, while those for CT were 75%, 66.7%, and 70.8%.

Aged↗

Intraoperative quick immunoperoxidase staining: a useful adjunct to routine pathological diagnosis in pancreatic carcinoma.

BACKGROUND/AIMS: This paper presents the results of a study comparing conventional and quick immunostaining. This paper aims to introduce the reliability of the immunoperoxidase method for rapid intraoperative pathological diagnosis of pancreatic cancer and the quick staining method. MATERIALS AND METHODS: Intrapancreatic extension and intraperitoneal spread of pancreatic duct cell carcinoma were evaluated by both conventional and quick immunostaining using antibodies against cancer-associated antigens CA19-9, DUPAN-2, and CEA for intraoperative pathological examination during the course of laparotomy. RESULTS: For the surgical cut margin, malignant lesions were identified in six of 30 cases by H-E staining. However, cancer cells were detected in 14 of 30 cases by the immunostaining method. On peritoneal washing cytological examination, malignant cells were recognized in four of 27 cases by conventional cytology. In two other cases, positive immunocytochemical findings were noted, and these clinical courses were suggestive of the immunostaining results. CONCLUSIONS: This immunostaining method was particularly useful in defining cancer cells surrounded by dense fibrous connective tissue and a very small number of cancer cells within the mesothelium, in which malignant cells are usually difficult to identify by conventional staining. Thus, the application of such immunostaining, together with conventional staining, on the cryostat sections of biopsy or on the peritoneal washings may provide sensitive information for intraoperative pathological examination and for selection of the appropriate surgical method.

Adult↗

Regional vascular resection using catheter bypass procedure for pancreatic cancer.

BACKGROUND/AIMS: To elucidate the indications for extended operation including main vessel resection in pancreatic cancer surgery, a clinical study was performed. The safety and clinical significance of portal vein resection in pancreatic cancer surgery have not yet been obtained in a large series. MATERIALS AND METHODS: Over a period of more than 10 years, 134 of 212 (63%) patients with pancreatic carcinoma underwent resection by extensive radical surgery. Portal vein resection was performed in 104 of 134 (78%) resected cases using catheter bypass procedure. The postoperative survival was investigated and a clinicopathological study was conducted. RESULTS: Operative death within 30 days after operation was observed in 11 of 134 (8%) resected cases. Postoperative survival rate correlated with the grade of portal vein invasion, which was diagnosed by preoperative or intraoperative portography. Survival for more than two years after operation was seen in cases of negative invasion on the margins of the resected specimens group even when portal system vein wall invasion was observed. CONCLUSION: Portal vein resection is performed safely using bypass procedure of the portal vein and is recommended to obtain a tumor-free surgical margin.

Catheterization, Peripheral↗